These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 27217696)
1. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. Joo MK; Park JJ; Chun HJ World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696 [TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635 [TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
4. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Kawakami H; Okamoto I Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587 [TBL] [Abstract][Full Text] [Related]
5. Drug sensitivity testing platforms for gastric cancer diagnostics. Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318 [TBL] [Abstract][Full Text] [Related]
6. Personalized medicine in gastric cancer: Where are we and where are we going? Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654 [TBL] [Abstract][Full Text] [Related]
7. Companion diagnostics for the targeted therapy of gastric cancer. Yoo C; Park YS World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953 [TBL] [Abstract][Full Text] [Related]
8. Precision and predictive medicine in urothelial cancer: are we making progress? Bellmunt J; Orsola A; Sonpavde G Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702 [TBL] [Abstract][Full Text] [Related]
9. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. Matsuoka T; Yashiro M World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624 [TBL] [Abstract][Full Text] [Related]
10. Clinical management of advanced gastric cancer: the role of new molecular drugs. De Vita F; Di Martino N; Fabozzi A; Laterza MM; Ventriglia J; Savastano B; Petrillo A; Gambardella V; Sforza V; Marano L; Auricchio A; Galizia G; Ciardiello F; Orditura M World J Gastroenterol; 2014 Oct; 20(40):14537-58. PubMed ID: 25356019 [TBL] [Abstract][Full Text] [Related]
11. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543 [TBL] [Abstract][Full Text] [Related]
12. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684 [TBL] [Abstract][Full Text] [Related]
13. Current and emerging therapies in unresectable and recurrent gastric cancer. Jou E; Rajdev L World J Gastroenterol; 2016 May; 22(20):4812-23. PubMed ID: 27239108 [TBL] [Abstract][Full Text] [Related]
14. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376 [TBL] [Abstract][Full Text] [Related]
16. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827 [TBL] [Abstract][Full Text] [Related]
17. c-Met targeting in advanced gastric cancer: An open challenge. Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023 [TBL] [Abstract][Full Text] [Related]
18. mTOR as a therapeutic target in patients with gastric cancer. Al-Batran SE; Ducreux M; Ohtsu A Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386 [TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. Yashiro M; Matsuoka T World J Gastroenterol; 2016 Feb; 22(8):2415-23. PubMed ID: 26937130 [TBL] [Abstract][Full Text] [Related]
20. The Evolving Landscape of HER2 Targeting in Breast Cancer. Moasser MM; Krop IE JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]